FIELD: bioengineering.
SUBSTANCE: modified epitope peptides MELK can be bonded with HLA-A*2402 and feature the higher ability of induction of cytotoxic T-lymphocytes than that of the epitope MELK peptide of a wild type.
EFFECT: higher efficiency of treatment.
12 cl, 10 dwg, 2 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
FOXM1 PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2560431C2 |
CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING SAME | 2009 |
|
RU2502740C2 |
KOC1-DERVIED PEPTIDE AND VACCINE INCLUDING SAME | 2015 |
|
RU2699542C2 |
URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2700881C2 |
CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2699543C2 |
CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
NEIL3 PEPTIDES AND VACCINES INCLUDING SAME | 2010 |
|
RU2600888C2 |
HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
Authors
Dates
2016-04-10—Published
2011-01-24—Filed